Devi Nallappan

Dr. Devi Nallappan


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
DNDevi Nallappan
Devi Nallappan
AFAgustine Nengsih Fauzi
Agustine Nengsih Fauzi
BKBalam Satheesh Krishna
Balam Satheesh Krishna
Praveen Kumar BasiviPraveen Kumar Basivi
Praveen Kumar Basivi
ARAvula Vijaya Kumar Reddy
Avula Vijaya Kumar Reddy
VISWESWARA RAO PASUPULETIVISWESWARA RAO PASUPULETI
VISWESWARA RAO PASUPULETI
Studies on green biosynthesis of newly engineered nanoparticles for their prominent medicinal applications are being the torch‐bearing concerns of the state‐of‐the‐art research strategies. In this concern, we have engineered the biosynthesized Luffa acutangula silver nanoparticles of flavonoid O‐glycosides in the anisotropic form isolated from aqueous leave extracts of Luffa acutangula, a popular traditional and ayurvedic plant in south‐east Asian countries. These were structurally confirmed by Ultraviolet‐visible (UV‐Vis), Fourier transform infrared spectroscopy accessed with attenuated total reflection (FTIR‐ATR) spectral analyses followed by the scanning electron microscopic (SEM) and the X‐ray diffraction (XRD) crystallographic studies and found them with the face‐centered cubic (fcc) structure. Medicinally, we have explored their significant antioxidant (DPPH and ABTS assays), antibacterial (disc diffusion assay on E. coli, S. aureus, B. subtilis, S. fecilis, and S. boydii), and anticancer (MTT assay on MCF‐7, MDA‐MB‐231, U87, and DBTRG cell lines) potentialities which augmented the present investigation. The molecular docking analysis of title compounds against 3NM8 (DPPH) and 1DNU (ABTS) proteins for antioxidant activity; 5FGK (Gram‐Positive Bacteria) and 1AB4 (Gram‐Negative Bacteria) proteins for antibacterial activity; and 4GBD (MCF‐7), 5FI2 (MDA‐MB‐231), 1D5R (U87), and 5TIJ (DBTRG) proteins for anticancer activity has affirmed the promising ligand‐protein binding interactions among the hydroxy groups of the title compounds and aspartic acid of the concerned enzymatic proteins. The binding energy varying from ‐9.1645 to ‐7.7955 for Cosmosioside (1, Apigenin‐7‐glucoside) and from ‐9.2690 to ‐7.8306 for Cynaroside (2, Luteolin‐7‐glucoside) implies the isolated compounds as potential bioactive compounds. In addition, the performed studies like QSAR, ADMET, bioactivity properties, drug scores, and toxicity risks confirmed them as potential drug candidates and aspartic acid receptor antagonists. This research auxiliary augmented the existing array of phytological nanomedicines with new drug candidates that are credible with multiple bioactivities.

21 May 2021 in Food & Function
Verified
Journal Article
Closed access
PDF file
DNDevi Nallappan
Devi Nallappan
KCKek Heng Chua
Kek Heng Chua
KOKien Chai Ong
Kien Chai Ong
CCChun Wie Chong
Chun Wie Chong
CTCindy Shuan Ju Teh
Cindy Shuan Ju Teh
UKUmah Rani Kuppusamy
Umah Rani Kuppusamy
Obesity is a driving factor in the onset of metabolic disorders. This study aims to investigate the effects of the myricetin derivative-rich fraction (MD) from Syzygium malaccense leaf extract on high-fat diet (HFD)-induced obesity and its associated complications and its influence on uncoupling protein-1 (UCP-1) and gut microbiota in C57BL/6J mice. Mice were randomly assigned into four groups (n = 6) and given a normal diet (ND) or high-fat diet (HFD) for 10 weeks to induce obesity. The HFD groups (continued with HFD) were administered 50 mg kg−1 MD (treatment), 50 mg kg−1 metformin (positive control) and normal saline (HFD and ND controls) daily for four weeks via oral gavage. The ten-week HFD-feeding resulted in hyperglycemia and elevated urinary oxidative indices. The subsequent MD administration caused significant weight reduction without appetite suppression and amelioration of insulin resistance, steatosis and dyslipidemia. Besides, MD significantly reduced lipid hydroperoxides and protein carbonyls in tissue homogenates and urine and elevated Trolox equivalent antioxidant capacity (TEAC), ferric reducing antioxidant power (FRAP) and reduced glutathione (GSH) and thus, alleviated oxidative stress. The weight reduction was correlated with downregulation of inflammatory markers and the increased UCP-1 level, suggesting weight loss plausibly through thermogenesis. The Akkermansia genus (reflects improved metabolic status) in the HFD50 group was more abundant than that in the HFD group while the non-enzymatic antioxidant markers were strongly associated with UCP-1. In conclusion, MD ameliorates obesity and its related complications possibly via the upregulation of UCP-1 and increased abundance of Akkermansia genus and is promising as a therapeutic agent in the treatment of obesity and its associated metabolic disorders.

26 July 2024
Verified
Book Chapter
Closed access
DNDevi Nallappan
Devi Nallappan
JKJayasree S. Kanathasan
Jayasree S. Kanathasan
Animal ethics encompasses moral, legal, and ethical standards governing human interactions with animals, including pre-clinical research and industrial settings. Animal welfare assesses animals' well-being and adaptability. Scientific evaluation of welfare has been significant, with scientists and philosophers working together to define the appropriate relationship between humans and animals. This chapter focuses on navigation ethics and animal welfare. It begins with an introduction to animal research ethics. Then, it delves into the general application, issues and development of animal ethics. The subsequent part highlights animal ethics in cellular agriculture and food production. It then discusses the connection between animal ethics and animal welfare. The chapter concludes with an overview of the challenges, limitations and prospects of integrating animal ethics and animal welfare. This review aims to provide new perspectives on ethics and animal welfare for researchers, policymakers, regulators, and others involved in animal research and welfare fields.

3 November 2023
Verified
Book Chapter
Closed access
DNDevi Nallappan
Devi Nallappan
JKJayasree S. Kanathasan
Jayasree S. Kanathasan
Sandeep PoddarSandeep Poddar
Sandeep Poddar
Researchers have directed their attention to the application of nanotechnology in the biomedical sciences owing to their promising effects. In light of this, the present chapter is a concerted effort to highlight the emerging application of nanotechnology in the field of biomedical sciences. The first part of the chapter describes the introduction to biomedical science, followed by an introduction to the development of nanotechnology, the types and characteristics of nanosized materials, and their potential therapeutic properties. Next, the present chapter describes the application of nanotechnology in biomedical sciences. It also highlights the current issues regarding the usage of nanotechnology in biomedical science, especially safety, regulation, and toxicity. This chapter aims to provide new insights into the extraordinary application of nanotechnology in the biomedical science field for researchers, policymakers, regulators, healthcare professionals, and others involved in the nano biomedical application field. Request access from your librarian to read this chapter's full text.

22 January 2024
Verified
Book Chapter
Closed access
DNDevi Nallappan
Devi Nallappan
JKJayasree S. Kanathasan
Jayasree S. Kanathasan
Sandeep PoddarSandeep Poddar
Sandeep Poddar
Andrew WareAndrew Ware
Andrew Ware
The gut microbiota is a potentially modifiable risk factor for various health complications. Therefore, advanced techniques are warranted to understand the relationship between gut microbiota, disease, and clinical relevance. This chapter focuses on the emerging application of artificial intelligence (AI) techniques in the studies of gut microbiota. It opens with a discussion on the role of gut microbiota in health, mentions an overview of AI techniques, and provides information on the application of AI in the study of the gut microbiome and its role in the diagnosis and treatment of diseases. It also gives a glimpse into the challenges and future direction of artificial intelligence in gut microbiome research. The chapter provides new insights into the extraordinary applications of AI in the study of the gut microbiome.

3 November 2023
Verified
Book Chapter
Closed access
JKJayasree S. Kanathasan
Jayasree S. Kanathasan
DNDevi Nallappan
Devi Nallappan
Sandeep PoddarSandeep Poddar
Sandeep Poddar
Andrew WareAndrew Ware
Andrew Ware
Nanotechnology has been applied in healthcare to cure diseases, especially cancer. Cancer is one of the heterogenous diseases which lacks symptoms in the early stage thus has made it difficult to cure at a later stage. Despite early detection, effective treatment is regarded as one of the major solutions to cure cancer. Nanomaterials play a prominent role in enhancing or replacing conventional treatments with specific and less-toxic drug delivery or therapy. The requirement and properties of nanomaterials as well as their applications in cancer therapies are discussed in this chapter. Various types of nanoparticles are available on the bench side, but these nanoparticles may lack effectiveness to treat cancer using a single treatment mode. Hence, this chapter also explores the applications of various types of hybrid nanoparticles used in multiple therapies as they have shown more effective and safer outcomes for cancer patients. The combination of cancer therapies and their successes have been discussed in this chapter which is the cutting-edge applications of cancer treatment today. Request access from your librarian to read this chapter's full text.